Clinical study of endovascular treatment for acute tandem vertebrobasilar artery occlusion

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300076130

Enrollment

Unknown

Registered

2023-09-26

Start date

2023-10-01

Completion date

Unknown

Last updated

2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular disease

Interventions

medicine group:None

endovascular treatment group:None

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) age 18 years or older; (2) Clinical symptoms and signs support acute ischemic stroke, and NIHSS score =3 (3) presentation within 24 hours, acute tandem VBO comfirmed by CTA, MRA or DSA (4) presentation within modified Rankin Scale (mRS) score <2 (5) sign the informed consent

Exclusion criteria

Exclusion criteria: (1) neuroimaging evidence of cerebral hemorrhage on presentation; (2) Allergy to contrast media; (3) Active bleeding; genetic or acquired bleeding predisposition, deficiency of anticoagulant factors; (4) current pregnancy or lactation; (5) a serious, advanced, or terminal illness; (6) a lack of follow-up information on outcomes at 90 days; (7) incomplete baseline imaging and time-metric data.

Design outcomes

Primary

Measure	Time frame
90-days good functional outcome;	—

Secondary

Measure	Time frame
The rate of sICH within 48 hours and 90-days mortality;	—

Countries

China

Contacts

Public ContactLi Wei

First Affiliated Hospital, Hainan Medical University

weiligysy@163.com+86 189 7657 4937

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026